design and synthesis of anti fungal agent((1,3-β-glucan, FKS1gen)

Takale Apurv, Tengle Saurabha, Anbhule Sachin

hsbpvts goi faculty of pharmacy, kashti

Abstract

The emergence of fungal infections, particularly those caused by *Candida* and *Aspergillus* species, has prompted an urgent need for novel antifungal agents due to the increasing resistance to existing treatments. One promising approach to combating fungal infections is the inhibition of key enzymes involved in the synthesis of *1,3-β-glucan*, a major component of the fungal cell wall. This study explores the design and synthesis of new antifungal compounds targeting the *FKS1* gene, which encodes the catalytic subunit of the *1,3-β-glucan synthase* enzyme. By utilizing structure-based drug design strategies, we identified several novel inhibitors that bind to the active site of FKS1, disrupting the biosynthesis of *1,3-β-glucan* and compromising the structural integrity of the fungal cell wall. The synthesized compounds were evaluated for antifungal activity against a range of pathogenic fungal strains, with a focus on minimizing toxicity to human cells. Results demonstrated potent antifungal effects, particularly in strains resistant to conventional azole and echinocandin therapies. Further mechanistic studies confirmed that the inhibitors specifically interfere with the *1,3-β-glucan* biosynthesis pathway. These findings suggest that targeting *FKS1* and the *1,3-β-glucan* synthesis pathway represents a promising strategy for the development of new antifungal agents, particularly in the face of rising antifungal resistance.

Introduction

Fungal Infection

Fungal infections represent a growing global health concern, particularly among immunocompromised individuals, such as cancer patients, organ transplant recipients, and those with HIV/AIDS. These infections can range from superficial conditions, such as athlete’s foot, to life-threatening systemic infections, such as candidiasis, aspergillosis, and cryptococcosis. The rising incidence of fungal infections, coupled with the limited number of antifungal agents and the emergence of drug-resistant fungal strains, underscores the need for the development of new and effective antifungal therapies.

Fungal infections, also known as mycoses, represent a diverse group of conditions caused by various fungal organisms that can affect virtually any part of the human body. These microscopic organisms are naturally present in the environment and on our bodies, but under certain conditions, they can multiply rapidly and cause infections ranging from mild to severe. While some fungi are harmless or even beneficial, others can cause significant health problems, particularly in people with compromised immune systems. The most common types include dermatophytes (which cause skin infections), candida (responsible for yeast infections), and aspergillus (which can cause respiratory infections).

These infections manifest differently depending on their location and the type of fungus involved. Superficial infections like athlete's foot typically cause itching, redness, and scaling of the skin, while systemic infections can lead to more serious symptoms such as fever, fatigue, and organ dysfunction. Environmental factors play a crucial role in fungal growth, with fungi thriving in warm, humid conditions. This explains why infections are more common in tropical climates and why areas of the body that tend to stay moist (like feet in enclosed shoes or skin folds) are particularly susceptible.

Treatment approaches vary based on the type and severity of the infection. While topical antifungal medications are often sufficient for surface infections, systemic infections may require oral or intravenous antifungal drugs.

Some infections, particularly those affecting the nails or deeper tissues, can be stubborn and may require prolonged treatment.

Recent medical research has shown increasing concern about antifungal resistance, similar to antibiotic resistance, highlighting the importance of proper diagnosis and appropriate use of antifungal medications. Healthcare providers are also noting a rise in opportunistic fungal infections, particularly in healthcare settings and among immunocompromised patients. This has led to enhanced prevention protocols in hospitals and greater emphasis on early detection and treatment of fungal infections in high-risk populations. Understanding the complex relationship between fungi and human health continues to be an important area of medical research, as new fungal threats emerge and treatment strategies evolve.

FKS1 gen

FKS1 (also known as FKS1 gene) is a gene found in fungal species that encodes for a crucial enzyme known as β-glucan synthase. This enzyme is responsible for the synthesis of 1,3-β-D-glucan, a critical component of the fungal cell wall. The proper function of β-glucan synthase is essential for maintaining the structural integrity and strength of the cell wall, which is vital for fungal cell survival, particularly in pathogenic fungi.

FKS1 (Fks1p in yeast) is an essential gene in many fungi, encoding a catalytic subunit of **β-1,3-glucan synthase**, which is responsible for synthesizing β-1,3-glucan, a polysaccharide forming the structural matrix of the fungal cell wall. This cell wall component is critical for maintaining cell integrity, shape, and overall viability, particularly in yeasts like *Saccharomyces cerevisiae* and pathogenic fungi such as *Candida albicans*.

Because of its role in antifungal resistance, FKS1 is a major research focus in medical mycology. Studies aim to understand its regulation, structure, and how mutations impact drug efficacy. Researchers are also looking into ways to overcome resistance, such as developing novel compounds that inhibit β-1,3-glucan synthase despite FKS1 mutations or identifying combination therapies that enhance echinocandin effectiveness.

In summary, FKS1 is a pivotal gene in fungal biology, essential for cell wall integrity and a significant target in antifungal therapy. Its role in drug resistance mechanisms highlights its clinical relevance and the ongoing need for research to address resistant fungal infections.

1,3-β-D-glucan

1,3-β-D-glucan is a type of polysaccharide composed of glucose units linked by β-1,3-glycosidic bonds. It is a significant component of the cell wall of many fungi, including Candida, Aspergillus, and Pneumocystis species, as well as certain bacteria and plants. Its role in the fungal cell wall makes it an important target for antifungal drug development, especially for echinocandin-class antifungals.

1,3-β-D-glucan consists of glucose units connected in a linear chain through β-1,3 linkages, often with branches attached via β-1,6 linkages.

1,3-β-D-glucan is a vital component of fungal cell walls and plays significant roles in fungal survival, immune recognition, and medical diagnostics. Its importance in fungal physiology and immunology makes it a valuable target for antifungal drugs and a useful biomarker for detecting invasive fungal infections.

Methodology

1. Target Identification and Validation

- Literature Review: Study available research to confirm 1,3-β-D-glucan synthase (FKS1) as a viable antifungal target, especially in pathogenic fungi like Candida and Aspergillus.

- Enzyme Structure Analysis: If structural data (e.g., crystal or cryo-EM structures) are available, analyze the active site and other binding pockets to identify essential residues for enzyme activity.

- Gene Knockout Studies (Optional): In cases where structural information is limited, use gene knockout or RNA interference techniques in model fungi to validate FKS1's role in cell wall synthesis and fungal viability.

2. In Silico Drug Design

- Molecular Docking: Use molecular docking software (e.g., AutoDock, Glide) to screen virtual libraries of compounds against the active site of 1,3-β-D-glucan synthase. Select compounds with the highest predicted binding affinity.

- Pharmacophore Modeling: Build a pharmacophore model based on known β-glucan synthase inhibitors, incorporating key features needed for activity (e.g., hydrogen bond donors/acceptors, hydrophobic regions).

- Molecular Dynamics Simulations: Run simulations on promising compounds to evaluate their stability within the enzyme binding pocket under physiological conditions, refining predictions on binding efficacy.

- Structure-Activity Relationship (SAR) Modeling: Perform SAR analysis to identify structural features that correlate with binding affinity, guiding compound modifications in later stages.

3. Synthesis of Lead Compounds

- Lead Compound Selection: Based on in silico predictions, select a set of promising compounds (typically 5-10) as lead candidates for synthesis.

- Organic Synthesis Techniques: Design synthetic pathways using conventional organic synthesis methods, such as coupling reactions, amide formation, or cyclization, to produce the lead compounds.

- Purification and Characterization: Purify compounds using chromatography (e.g., HPLC), and confirm their structures via NMR, mass spectrometry (MS), and IR spectroscopy.

4. In Vitro Testing and Optimization

- Enzyme Inhibition Assay: Perform enzyme assays with purified 1,3-β-D-glucan synthase to measure inhibitory activity (IC_{50} values). Use fluorescence or absorbance-based assays that report on the enzyme's activity level.

- Fungal Growth Assay (MIC Testing): Test the synthesized compounds against various fungal strains (e.g., Candida albicans, Aspergillus fumigatus) to determine minimum inhibitory concentrations (MICs). Standard MIC assays involve serial dilution and observing growth inhibition.

- Cytotoxicity Testing: Assess toxicity in mammalian cell lines (e.g., HEK293, human liver cells) to ensure selectivity for fungal cells, avoiding compounds that exhibit high toxicity to human cells.

- Structure-Activity Relationship (SAR) Refinement: Based on enzyme inhibition and fungal growth results, refine the chemical structure of the lead compounds, focusing on increasing potency, selectivity, and reducing toxicity. This step may involve adding or removing functional groups or altering the compound's stereochemistry.

5. In Vivo Testing and Pharmacokinetic/Pharmacodynamic (PK/PD) Studies

- Animal Model Studies: Evaluate promising compounds in animal models of fungal infection (e.g., mice or rats) to assess antifungal efficacy in a physiological environment. Monitor reduction in fungal burden in infected tissues as well as any signs of toxicity.

- Pharmacokinetics (PK): Measure parameters such as absorption, distribution, metabolism, and elimination in animal models. Key metrics include half-life, bioavailability, and tissue distribution.

- Pharmacodynamics (PD): Assess the dose-response relationship to determine the minimum effective dose and duration of the compound's antifungal action in vivo.

- Toxicity Studies: Conduct acute and chronic toxicity studies to identify the compound's safety profile, establishing the maximum tolerated dose (MTD).

6. Resistance Testing and Combination Studies

- Resistance Assays: Test compound efficacy against fungal strains with common resistance mutations in FKS1 (e.g., echinocandin-resistant Candida) to assess susceptibility.

- Combination Therapy Testing: Examine the potential for combining the new compound with existing antifungals, such as azoles, to determine if synergistic effects improve efficacy or delay resistance onset.

7. Formulation Development and Stability Testing

- Formulation: Develop a suitable drug formulation, possibly improving solubility, stability, or bioavailability. This may involve lipid-based formulations, nanoparticle encapsulation, or creating salts of the compound.

- Stability Testing: Conduct stability studies to ensure compound integrity over time under various storage conditions (temperature, light, humidity).

8. Scale-Up and Preclinical Preparation

- Scale-Up Synthesis: Refine synthesis to ensure that the compound can be produced on a larger scale with consistent quality and purity, preparing for preclinical and clinical testing.

- Regulatory Compliance: Document all safety, efficacy, and stability data following regulatory guidelines to prepare for potential clinical trials.

The synthesis of the FKS1 gene typically involves cloning and expression techniques that allow researchers to produce the gene for further studies, like understanding its role in fungal cell wall biosynthesis or developing targeted antifungal treatments. Here’s a methodology for synthesizing and expressing the FKS1 gene:

1. Gene Sequence Design and Optimization

- Sequence Selection: Obtain the nucleotide sequence for the FKS1 gene from a database (e.g., GenBank). If studying specific fungi (e.g., Candida albicans or Aspergillus fumigatus), use the species-specific FKS1 sequence.

- Codon Optimization: If expressing the FKS1 gene in a different organism (like E. coli for protein expression), codon optimization may be needed. Adjust codons to match the preferred codon usage of the host organism, ensuring efficient transcription and translation.

- Addition of Tags (Optional): To simplify purification, add tags like His-tags or FLAG-tags to the gene sequence, which can help with downstream purification steps.

2. Gene Synthesis

- Synthetic Gene Synthesis: Send the optimized FKS1 sequence to a commercial gene synthesis service, which can synthesize the gene as a double-stranded DNA (dsDNA) fragment. Alternatively, perform in-house synthesis if equipped with the resources.

- PCR Amplification: If needed, amplify the synthesized gene using polymerase chain reaction (PCR) to generate sufficient quantities of DNA for cloning.

3. Cloning into an Expression Vector

- Choose an Expression Vector: Select a suitable vector that allows for high levels of gene expression in the host cell. For studying the FKS1 gene, expression systems in yeast (like Saccharomyces cerevisiae) or bacteria (e.g., E. coli) are common.

- Restriction Enzyme Digestion and Ligation: Use restriction enzymes to cut both the synthesized FKS1 gene and the vector at specific sites. Then, ligate the gene into the vector to create a recombinant plasmid.

- Alternative Cloning Methods: If restriction sites are not available, use techniques like Gibson Assembly or ligation-independent cloning to insert the gene into the vector.

4. Transformation and Selection

- Transformation into Host Cells: Introduce the recombinant plasmid into competent host cells (e.g., E. coli for initial propagation or S. cerevisiae for expression) through transformation methods like heat shock or electroporation.

- Selection and Screening: Grow transformed cells on selective media containing antibiotics or other markers. Confirm successful insertion by colony PCR or restriction enzyme digestion.

5. Expression of FKS1 Protein

- Induction of Expression: In an expression host (like yeast or bacterial cells), induce FKS1 expression using an inducer (e.g., IPTG for E. coli or galactose for yeast expression systems).

- Monitor Protein Expression: Verify protein expression via SDS-PAGE and Western blotting, particularly if tags were added to aid in detection.

6. Protein Purification and Analysis

- Cell Lysis and Purification: Lyse the cells and purify the FKS1 protein using affinity chromatography, especially if a His-tag or other affinity tag was added.

- Functional Assays: Analyze the enzyme's function by measuring its activity in synthesizing β-1,3-glucan in vitro. This step can confirm the protein's activity and assess potential inhibitors' effects for antifungal research.

The synthesis of 1,3-β-D-glucan (beta-glucan) involves biochemical and enzymatic processes that polymerize glucose into a long-chain polysaccharide. In fungi, this process is crucial for cell wall integrity and is catalyzed by the enzyme 1,3-β-D-glucan synthase. Here's an outline of how 1,3-β-glucan is synthesized both in natural settings (fungal cells) and potentially in vitro using enzymatic methods.

1. Natural Synthesis of 1,3-β-D-Glucan in Fungi

In fungal cells, 1,3-β-D-glucan is synthesized by the enzyme 1,3-β-D-glucan synthase, which is a membrane-bound enzyme complex responsible for polymerizing glucose into β-glucan. Here's how it occurs:

- Substrate: The enzyme uses UDP-glucose as the activated form of glucose, which is the precursor for 1,3-β-D-glucan synthesis.

- Enzyme Activation: 1,3-β-D-glucan synthase is typically activated by intracellular signaling molecules, such as GTP-binding proteins, which control the enzyme's activity based on the cell's needs for cell wall synthesis.

- Polymerization Process: The enzyme catalyzes the transfer of glucose from UDP-glucose to the growing β-glucan chain. This process links glucose molecules via β-1,3-glycosidic bonds, forming long chains of 1,3-β-D-glucan.

- Cell Wall Integration: As the β-glucan is synthesized, it is extruded through the cell membrane and incorporated into the cell wall, where it cross-links with other cell wall components, such as chitin and proteins.

2. In Vitro Synthesis of 1,3-β-D-Glucan

In a laboratory setting, the synthesis of 1,3-β-D-glucan can be achieved using purified 1,3-β-D-glucan synthase enzyme and UDP-glucose as the substrate. Here's a basic methodology for in vitro synthesis:

- Preparation of UDP-Glucose : UDP-glucose can be purchased or synthesized and acts as the glucose donor for the polymerization process.

- Enzyme Source: Isolate or purchase purified 1,3-β-D-glucan synthase. This enzyme may be extracted from fungal cells or produced via recombinant expression in yeast or bacteria.

- Reaction Setup: Mix the enzyme with UDP-glucose in a buffered solution that mimics intracellular conditions (optimal pH, temperature, and presence of necessary cofactors like Mg^{2+} or Ca^{2+} ions).

- Polymerization Reaction: Under optimal conditions, the enzyme will catalyze the transfer of glucose units from UDP-glucose to form the β-1,3 linkages, creating 1,3-β-D-glucan.

- Product Isolation: Once synthesized, the 1,3-β-D-glucan can be purified from the reaction mixture using filtration or precipitation techniques. It can then be analyzed via techniques like NMR spectroscopy or chromatography to confirm the structure and purity.

3. Chemical Synthesis of 1,3-β-D-Glucan (Alternative)

While enzymatic synthesis is common, 1,3-β-D-glucan can also be synthesized chemically, though this is more challenging and less efficient due to the difficulty of selectively forming β-1,3-glycosidic bonds without enzymes.

- Protecting Group Strategy: Chemical synthesis involves using protecting groups on glucose to prevent unwanted side reactions and guide the formation of β-1,3 linkages.

- Glycosylation Reactions: Specialized glycosylation reactions create the β-1,3-glycosidic linkages between glucose monomers.

- Polymer Chain Assembly: Repeating the glycosylation steps builds the desired β-1,3-linked glucan chain

Method for Designing and Synthesizing Antifungal Agents Targeting 13-Beta-Glucan Synthase

1. Target Identification

- Objective: Target the enzyme 13-beta-glucan synthase (Fks1/Fks2), which catalyzes the formation of 13-beta-glucan, a major component of the fungal cell wall.

- Approach: Investigate the enzyme's role in fungal cell wall synthesis and identify the enzyme's catalytic site for possible inhibitor binding.

2. Computational Design (Structure-Based Drug Design)

- Obtain Structure: If available, retrieve the crystal structure of 13-beta-glucan synthase (from databases like PDB) or use computational methods (e.g., homology modeling) to model its structure.

- Docking Studies: Use molecular docking to screen for potential inhibitors that could bind to the enzyme’s active site (similar to UDP-glucose, its natural substrate).

- Selectivity and Binding: Analyze binding affinity, interaction networks (e.g., hydrogen bonds, van der Waals interactions), and selectivity for fungal 13-beta-glucan synthase.

3. Design of Inhibitors

- Types of Inhibitors : Design inhibitors that either mimic the substrate (competitive inhibitors) or bind to an allosteric site (non-competitive inhibitors).

- Sugar Analogs: Modify UDP-glucose or other sugar analogs to create molecules that can inhibit the enzyme by mimicking the natural substrate without being processed.

- Peptide-Based Inhibitors: Design peptides or small molecules that bind to the enzyme's active site or disrupt its conformation.

- Optimization: Based on the computational results, optimize the chemical structure of the inhibitor for better binding affinity, stability, and specificity.

4. Synthesis of the Inhibitors

- Chemical Synthesis: Use techniques like solid-phase synthesis or solution-phase synthesis to chemically synthesize the designed inhibitors.

- Functional Group Modification: Include functional groups (e.g., hydroxyl, amino, carboxyl) that interact favorably with the enzyme's active site.

5. In Vitro Screening

- Enzyme Assay: Test the synthesized inhibitors against 13-beta-glucan synthase in vitro. This can involve using fungal cell extracts or purified enzyme preparations.

- HPLC or Mass Spectrometry: Quantify the production of 13-beta-glucan to determine the degree of inhibition.

- IC50 Measurement: Determine the IC50 value (the concentration at which the inhibitor reduces enzyme activity by 50%).

6. Structure-Activity Relationship (SAR) Studies

- SAR Optimization: Modify the chemical structure of initial inhibitors based on the SAR data to improve potency, bioavailability, and selectivity. Consider aspects like molecular weight, hydrophobicity, and solubility.

- Test Derivatives: Synthesize and test derivatives to identify the most effective compounds.

7. Fungal Cell-Based Assays

- MIC Testing: Test the inhibitors against various fungal species (e.g.,Candida albicans, Aspergillus fumigatu, Saccharomyces cerevisiae) to measure their minimum inhibitory concentration (MIC).

- Fungal Growth Inhibition: Perform fungal growth inhibition assays to determine the efficacy of the inhibitor in disrupting cell wall synthesis and fungal growth.

8. In Vivo Studies

- Animal Models: If the inhibitors show promise in vitro, test their pharmacokinetics, toxicity, and efficacy in animal models (e.g., murine models of fungal infections).

- Safety and Efficacy: Assess toxicity and therapeutic index, ensuring the inhibitor does not negatively affect human cells.

9. Optimization and Clinical Development

- Lead Optimization: Refine the most promising compound by optimizing its pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion (ADME).

- Preclinical to Clinical Transition: If results are favorable, begin preclinical development, including safety pharmacology and toxicology studies, before transitioning to clinical trials.

Conclusion

Designing and synthesizing an antifungal agent targeting 13-beta-glucan synthase holds significant potential for combating fungal infections by disrupting the integrity of the fungal cell wall. The method outlined involves a

multi-step approach, starting with understanding the enzyme's role in fungal biology, followed by computational modeling, inhibitor design, and chemical synthesis. Through in vitro assays, structure-activity relationship studies, and cell-based testing, the most promising compounds can be identified and optimized.

In addition, successful inhibitors could provide a novel class of antifungal agents, complementing existing treatments and addressing issues such as resistance. Moving from initial compound synthesis to in vivo efficacy and safety studies further ensures that potential drugs meet the necessary criteria for therapeutic application. Ultimately, targeting 13-beta-glucan synthas represents a promising strategy in the development of more effective antifungal therapies, with the potential to significantly improve patient outcomes in the treatment of invasive fungal infections.

Reference

1. Wagener, J., Striegler, K. & Wagener, N. α- and β-1,3-Glucan synthesis and remodeling. *Curr. Top. Microbiol. Immunol.* **425**, 53–82 (2020).
2. Gow, N. A. R., Latge, J. P. & Munro, C. A. The fungal cell wall: structure, biosynthesis, and function. *Microbiol. Spect.* https://doi.org/10.1128/microbiolspec.FUNK-0035-2016 (2017).
3. Perfect, J. R. The antifungal pipeline: a reality check. *Nat. Rev. Drug Discov.* **16**, 603–616 (2017).
4. Inoue, S. B. et al. Characterization and gene cloning of 1,3-β-D-glucan synthase from *Saccharomycescerevisiae*. *Eur. J. Biochem.* **231**, 845–854 (1995).
5. Douglas, C. M. et al. The *Saccharomyces cerevisiae* FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-β-D-glucan synthase. *Proc. Natl Acad. Sci. USA* **91**, 12907–12911 (1994).
6. Fisher, M. C., Hawkins, N. J., Sanglard, D. & Gurr, S. J. Worldwide emergence of resistance to antifungal drugs challenges human health and food security. *Science* **360**, 739–742 (2018).
7. Perlin, D. S., Rautemaa-Richardson, R. & Alastruey-Izquierdo, A. The global problem of antifungalresistance: prevalence, mechanisms, and management. *Lancet Infect. Dis.* **17**, e383–e392 (2017).
8. Hoenigl, M. Invasive fungal disease complicating COVID-19: when it rains it pours. *Clin. Infect. Dis.* **73**, e1645–e1648 (2021).
9. Hoenigl, M. et al. The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin. *Drugs* **81**, 1703–1729 (2021).
10. Brown, G. D. et al. Hidden killers: human fungal infections. *Sci. Transl. Med.* **4**, 165rv113 (2012).
11. Beauvais, A., R. Drake, K. Ng, M. Diaquin, and J. P. Latge. 1993. Characterization of the 1,3-b-glucan synthase of Aspergillus fumigatus. J. Gen. Microbiol. 139:3071–3078.
12. Borgia, P. T., and C. L. Dodge. 1992. Characterization of Aspergillus nidulans mutants deficient in cell wall chitin or glucan. J. Bacteriol. 174:377–383.
13. . Bouffard, F. A., R. A. Zambias, J. F. Dropinski, J. M. Balkovec, M. L. Hammond, G. K. Abruzzo, K. F. Bartizal, J. A. Marrinan, M. B. Kurtz, D. C. McFadden, K. H. Nollstadt, M. A. Powles, and D. M. Schmatz. 1994. Synthesis and antifungal activity of novel cationic pneumocandin Bo derivatives. J. Med. Chem. 37:222–225.
14. Cabib, E., B. Bowers, A. Sburlati, and S. J. Silverman. 1988. Fungal cell wall synthesis: the construction of a biological structure. Microbiol. Sci. 5:370– 375.
15. Douglas, C. M., F. Foor, J. A. Marrinan, N. Morin, J. B. Nielsen, A. M. Dahl, P. Mazur, W. Baginsky, W. Li, M. El-Sherbeini, J. A. Clemas, S. M. Mandala, B. R. Frommer, and M. B. Kurtz. 1994. The Saccharomyces cerevisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-b-D-glucan synthase. Proc. Natl. Acad. Sci. USA 91:12907–12911.
16. Douglas, C. M., J. A. Marrinan, W. Li, and M. B. Kurtz. 1994. A Saccharomyces cerevisiae mutant with echinocandin-resistant 1,3-b-D-glucan synthase. J. Bacteriol. 176:5686–5696.
17. El-Sherbeini, M., and J. A. Clemas. 1995. Concomitant nikkomycin Z supersensitivity of an echinocandin-resistant mutant of Saccharomyces cerevisiae. Antimicrob. Agents Chemother. 39:200–207.
18. Mazur, P., N. Morin, W. Baginsky, M. El-Sherbeini, J. A. Clemas, J. B. Nielsen, and F. Foor. 1995. Differential expression and function of two homologous subunits of yeast 1,3-b-D-glucan synthase. Mol. Cell. Biol. 15: 5671–5681.
19. Mitchell, A., C. M. Douglas, J. d'Ippolito, G. J. Shei, and M. B. Kurtz. 1995. Homology of genes that confer echinocandin resistance in S. cerevisiae and C. albicans, p. 133. In Abstracts of the 1995 Meeting on Yeast Cell Biology. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.

20. Ram, A. F. J., S. S. C. Brekelmans, L. J. W. Oehlen, and F. M. Klis. 1995. Identification of 2 cell-cycle-regulated genes affecting the b-1,3-glucan content of cell-walls in Saccharomyces cerevisiae. FEBS Lett. 358:165–170.
21. Yang, L., et al. (2014). "Design, synthesis, and antifungal activity of novel triazole derivatives as potential antifungal agents." reports the design, synthesis, and biological evaluation of triazole derivatives, which are a class of antifungal drugs commonly used to treat infections caused by fungi.
22. Dykstra, J. M., et al. (2015). "Design and synthesis of inhibitors of fungal β-glucan synthase: A novel class of antifungal agents." focuses on the design and synthesis of echinocandin-like inhibitors, which target fungal β-glucan synthase, a key enzyme in fungal cell wall synthesis.
23. Huang, J., et al. (2020). "Design, synthesis, and evaluation of new antifungal agents based on natural products presents the design and synthesis of novel antifungal agents derived from natural products and explores their mechanisms of action.
24. Kouadio, J. L., et al. (2019). "Synthesis and antifungal activity of novel hybrid compounds derived from azole and allylamine antifungal agents." describes the synthesis of hybrid compounds that combine elements of azole and allylamine antifungals, aiming to improve antifungal potency and combat resistance.